Neurovista

Announced at the World Stroke Congress, Stephan Mayer reported on reduced disability in patients with ICH treated with Factor VIIa (see this Washington Post article)

Dr. Anton Wellstein, Georgetown University.  on therapeutic targeting of tyrosine kinase receptors.

Yale University scientists target AAV expression to specific cell types within the brain..

Nanoparticles to image the brain.  Read about the OHSU study here.